Tottori, Japan
Tottori, Japan

National University Corporation Tottori University , abbreviated to Toridai , is a national university in Japan. The main campus is located in Koyamachō-Minami, Tottori City, Tottori Prefecture. Another campus, the Faculty of Medicine, is located on the Yonago Campus in Yonago, Tottori. Wikipedia.


Time filter

Source Type

A novel therapeutic drug for malignant tumors, cancer stem cells, or fibrosis is obtained. A therapeutic drug for malignant tumors or cancer stem cells is used that includes at least one compound selected from the group consisting of compounds represented by formulas (1), (2), and (5), a salt thereof, or a solvate thereof. Alternatively, a therapeutic drug for fibrosis can be used that includes at least one compound selected from the group consisting of compounds represented by formulas (1), (2), and (5), a salt thereof, or a solvate thereof.


Patent
Tottori University and Tokyo Women's Medical University | Date: 2014-02-19

The purpose is to select low-molecular-weight compounds which are effective in inducing differentiation of mesenchymal stem cell into hepatocyte and to develop a safe differentiation-inducing method having excellent efficiency of differentiating mesenchymal stem cell into hepatocyte. Provided are at least one compound selected from the group consisting of compounds represented by formulae (1) and (2), a salt thereof, or a solvate of them; a differentiation inducer comprising at least one compound selected from the group consisting of compounds represented by formulae (1) and (2), a salt thereof, or a solvate of them; and a differentiation inducer comprising a compound represented by formula (8), a salt thereof, or a solvate of them.


Patent
Daio and Tottori University | Date: 2016-11-02

To know an absorption and diffusion state with time of drainage. In a state in which an absorbent article 2 is put on a human body type dummy doll 20 equipped with a body fluid-supplying means, the absorbent article 2 is photographed after the fluid is excreted from the dummy doll 20 by an X-ray CT apparatus 1; and at least one absorption modes of absorption modes of the drainage into the absorbent article 2 after the excretion in the state in which the absorbent article 2 is put on the dummy doll 20, and absorption dynamics of the drainage on the absorbent article 2 after the excretion is displayed/analyzed based on the photographed image.


Patent
Daio and Tottori University | Date: 2016-11-02

The present invention aims at providing a disposable diaper having excellent maintainability of a surface space and capable of being easily produced. It is characterized in that a lower layer absorbent body (23B) has, at least at center of a crotch portion (C2) in a width direction, an elongated lower layer through section (60) piercing in a thickness direction and extending in a front-back direction; an upper layer absorbent body (23A) has an upper layer through section (50) piercing in the thickness direction at least within a range corresponding to the lower layer through section (60) in the front-back direction, the upper layer through section (50) has an elongated middle section (51) extending in the front-back direction so as to be located above the lower layer through section (60), and extending sections (52) which extend, in the width direction, from both sides of a back side position of the middle section (51), and a side edge of the extending section (52) has a shape in which at least a part of the front side thereof is located further outside in the width direction toward the back side.


Kuwamoto S.,Tottori University
Human Pathology | Year: 2011

Recent outstanding research has rapidly revealed new aspects of the biology, etiology, and clinicopathology of Merkel cell carcinoma, a rare but highly aggressive neuroendocrine skin malignancy that affects the elderly and immunosuppressed patients. Molecular biological studies, especially the discovery of Merkel cell polyomavirus, have shed new light on the pathogenesis of the disease. Increasing evidence strongly suggests that this virus is causally related to the development of Merkel cell carcinoma. On the other hand, many studies have also indicated that a subset (approximately 20%) of Merkel cell carcinomas are not likely to be associated with the virus. Tumors with and without the virus have been shown to be significantly different in prognosis, oncogene expression, and histologic appearance, suggesting that they have different etiologies. Moreover, studies on the histopathology, immunohistochemistry, and cytogenetics have revealed several biological factors that are related to the clinical behavior and prognosis of the disease. This review summarizes the advances in the molecular biology of Merkel cell carcinoma based on recent study results. Although the exact molecular pathway of the pathogenesis of Merkel cell carcinoma remains unclear, further understanding of the pathophysiology of this tumor is expected to result in novel therapeutic approaches for management of the disease and contribute to better patient outcomes. © 2011 Elsevier Inc. All rights reserved.


It is an object of the present invention to evaluate the induction of a drug-metabolizing enzyme by a test substance more accurately than ever before, by simple operations, using a vector in which a reporter gene is connected downstream of the expression control region of a drug-metabolizing enzyme gene and a cell into which the aforementioned vector is introduced. The present invention provides a vector for producing a cell that is used for evaluation of the induction of a drug-metabolizing enzyme by a test substance and the cytotoxicity of the test substance, the vector comprising an expression control region of a fetus-specific gene, a first reporter gene, an expression control region of a drug-metabolizing enzyme gene, and a second reporter gene, wherein the first reporter gene is located downstream of the expression control region of the fetus-specific gene and the second reporter gene is located downstream of the expression control region of the drug-metabolizing enzyme gene. In addition, the present invention also provides a cell comprising the aforementioned vector and a method for evaluating induction of a drug-metabolizing enzyme by a test substance and cytotoxicity of the test substance using the vector.


Patent
Tottori University and The Chemo Sero Therapeutic Research Institute | Date: 2014-11-20

This invention provides a vaccinia virus that grows specifically in a cancer cell and damages such cancer cell and the use of such virus for treatment of cancer. Such mitogen-activated protein kinase-dependent vaccinia virus strain lacks functions of vaccinia virus growth factor (VGF) and O1L, it does not grow in normal cells but grows specifically in cancer cells, and it has oncolytic properties that specifically damage cancer cells.


Patent
Tottori University and The Chemo Sero Therapeutic Research Institute | Date: 2016-09-28

This invention provides a vaccinia virus that grows specifically in a cancer cell and damages such cancer cell and the use of such virus for treatment of cancer. Such mitogen-activated protein kinase-dependent vaccinia virus strain lacks functions of vaccinia virus growth factor (VGF) and O1L, it does not grow in normal cells but grows specifically in cancer cells, and it has oncolytic properties that specifically damage cancer cells.


Patent
Teijin Pharma Ltd and Tottori University | Date: 2014-12-03

The purpose of the present invention is to provide a novel therapeutic agent or a novel prophylactic agent for diseases associated with abnormal glucose metabolism. The present invention is a therapeutic agent or a prophylactic agent for diseases associated with abnormal glucose metabolism, which comprises a 2-phenylthiazole compound represented by formula (I) or a pharmaceutically acceptable salt thereof as an active ingredient.


Patent
Tottori University | Date: 2014-08-28

Disclosed is a novel process for producing a Muse cell-like cell or a novel method for extending the replicative life span of a cell population. Provided is a process for producing a Muse cell-like cell, comprising the step of inhibiting the expression or function of ELAVL2, TEAD1, or GATAD2B. At this time, siRNA or shRNA may be used to inhibit the expression or function of ELAVL2, TEAD1, or GATAD2B.

Loading Tottori University collaborators
Loading Tottori University collaborators